Be a Smart Investor

Thursday, March 31, 2022

Lulu's Fashion Lounge Q4 Results Beat Street View, Revenue Outlook Strong; Shares Up 10%

Lulu's Fashion Lounge Holdings, Inc. (LVLU) Thursday reported a loss for the fourth quarter, that was narrower than Wall Street's estimates, driven by revenue growth. The company also issued a strong revenue outlook for the full year 2022. Following the news, shares of Lulu's Fashion gained nearly 10%.

from RTT - Earnings https://ift.tt/wHXs0yt
via IFTTT

Paychex Adjusts Full Year Guidance Upward

Paychex, Inc. (PAYX) said, for fiscal 2022, the company now expects: adjusted earnings per share to grow in the range of 22.5% to 23%. Total revenue is now anticipated to grow in the range of 12% to 13%. Management Solutions revenue is now projected to grow in the range of 12% to 13%. In December, the company projected: adjusted earnings per share growth in the range of 18% to 20%; and total revenue increase in the range of 10% to 11%.

from RTT - Earnings https://ift.tt/T1li46k
via IFTTT

BioNTech Swings To Profit In Q4

Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE announced Wednesday a profit for the fourth quarter compared to a loss last year, driven by the continued global delivery of its COVID-19 vaccine. The company also reiterated its COVID-19 vaccine revenue guidance for the full-year 2022.

from RTT - Earnings https://ift.tt/rM1q6Re
via IFTTT

China Automotive Systems Swings To Profit In Q4

China Automotive Systems, Inc. (CAAS) announced Wednesday that net income attributable to parent company's common shareholders for the fourth quarter was $5.0 million or $0.16 per share, compared to a net loss of $3.2 million or $0.10 per share in the prior-year quarter.

from RTT - Earnings https://ift.tt/hIRz0uP
via IFTTT

IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4

SomaLogic Inc. (SLGC), a commercial-stage AI-data driven proteomics technology company, expects revenue for 2022 to grow 29% to 35% over the prior year. For full year 2022, the company expects revenue to range between $105 million and $110 million, which represents 29% to 35% growth over last year. Revenue for the full year 2021 was $81.6 million.

from RTT - Earnings https://ift.tt/kcfw9l5
via IFTTT

McCormick Reiterates FY22 Outlook

While reporting financial results for the first quarter on Tuesday, flavor maker McCormick & Co., Inc. (MKC) reiterated its earnings, adjusted earnings and sales growth guidance for the full year 2022.

from RTT - Earnings https://ift.tt/9MAplzY
via IFTTT

ETNB To Report ENTRIGUE Data In Q2, MDVL's Q1 Revenue To More Than Double, OCUP On Watch

Landos Biopharma Inc. (LABP) expects to initiate a phase 2b study of Omilancor in ulcerative colitis later this year. NX-13, for the potential treatment of Ulcerative Colitis, and LABP-104, for the potential treatment of systemic lupus erythematosus and/or rheumatoid arthritis, are the other investigational drugs in the pipeline

from RTT - Earnings https://ift.tt/Tfx0hIk
via IFTTT